Literature DB >> 1275541

Serum creatine phosphokinase in normal newborns.

N Gilboa, J R Swanson.   

Abstract

Serum creatine phosphokinase (CPK) activity in 70 normal newborns was found to be significantly higher than the normal values found in adults or older children, and in some cases reached a level up to 10 times normal. It declined to near normal activity during the first 4 days and to normal level of activity by age 6-10 weeks. No clear correlation between birth trauma and increase in serum CPK activity was shown. CPK activity in cord blood was lower than in venous and capillary blood. Because of the increased CPK activity found in normal newborns, screening for Duchenne-type muscular dystrophy should be postponed for a few weeks after delivery.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1275541      PMCID: PMC1545939          DOI: 10.1136/adc.51.4.283

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  6 in total

1.  An improved procedure for serum creatine phosphokinase determination.

Authors:  S B Rosalki
Journal:  J Lab Clin Med       Date:  1967-04

2.  Early diagnosis and treatment of rapidly developing Duchenne De Boulogne type myopathy (type DDB I).

Authors:  J Demos
Journal:  Am J Phys Med       Date:  1971-12

3.  Utilization of capillary blood for serum enzyme analysis.

Authors:  J B Bodensteiner; H Zellweger
Journal:  Helv Paediatr Acta       Date:  1970-10

4.  Creatine phospholinase in normal neonates and young infants.

Authors:  J B Bodensteiner; H Zellweger
Journal:  J Lab Clin Med       Date:  1971-05

5.  Creatine phosphokinase activity in serum of newborn infants as an indicator of fetal trauma during birth.

Authors:  N Rudolph; R T Gross
Journal:  Pediatrics       Date:  1966-12       Impact factor: 7.124

6.  Newborn screening for Duchenne muscular dystrophy.

Authors:  H Zellweger; A Antonik
Journal:  Pediatrics       Date:  1975-01       Impact factor: 7.124

  6 in total
  9 in total

1.  Duchenne muscular dystrophy: early diagnosis, and screening.

Authors: 
Journal:  Arch Dis Child       Date:  1976-12       Impact factor: 3.791

Review 2.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

Review 3.  Screening for Duchenne muscular dystrophy.

Authors:  V Dubowitz
Journal:  Arch Dis Child       Date:  1976-04       Impact factor: 3.791

4.  Birth asphyxia-predictors of outcome and management.

Authors:  R H Merchant
Journal:  Indian J Pediatr       Date:  1985 Nov-Dec       Impact factor: 1.967

5.  Serum creatine phosphokinase (CPK) isoenzymes in perinatal asphyxia.

Authors:  M M Thangavel; P L Chordia; N Rudolph
Journal:  Indian J Pediatr       Date:  1982 Sep-Oct       Impact factor: 1.967

6.  Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK).

Authors:  Stuart J Moat; Donald M Bradley; Rachel Salmon; Angus Clarke; Louise Hartley
Journal:  Eur J Hum Genet       Date:  2013-01-23       Impact factor: 4.246

7.  Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy.

Authors:  L M Drummond
Journal:  Arch Dis Child       Date:  1979-05       Impact factor: 3.791

8.  Serum creatine kinase levels in normal females.

Authors:  R K Satapathy; R Skinner
Journal:  J Med Genet       Date:  1979-02       Impact factor: 6.318

9.  Creatine kinase-MM concentration in dried blood spots from newborns and implications for newborn screening for Duchenne muscular dystrophy.

Authors:  Sunju Park; Breanne Maloney; Michele Caggana; Norma P Tavakoli
Journal:  Muscle Nerve       Date:  2022-04-06       Impact factor: 3.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.